Monitor Q3 2026 earnings call for actual revenue figures and updated hospital adoption targets. The 44% sequential increase in ordering hospitals is a positive leading indicator, but revenue conversion and utilization rates remain unquantified.
Price Chart
Executive Summary
Humacyte provided a Q3 2026 commercial update highlighting accelerating Symvess adoption, with hospitals ordering the product increasing 44% from 34 to 49 during the quarter. The press release did not disclose revenue or EPS figures, but the sequential monthly acceleration in ordering activity suggests growing commercial traction for the FDA-approved vascular conduit.
Key Facts
- Hospitals ordering Symvess increased 44% in Q3 2026, from 34 to 49 hospitals as of September 30, 2026
- New hospital ordering activity increased sequentially each month of Q3 2026
- Commercial momentum driven by expanding hospital orders and surgeon interest
- Symvess is FDA-approved for extremity arterial injury when urgent revascularization is needed
- Company on track to potentially surpass its goal of adding 20 new hospitals by year-end
Financial Impact
No revenue or EPS figures disclosed; commercial update only
Risk Factors
- Symvess carries a boxed warning for graft failure including rupture and anastomotic failure
- Commercial adoption may not translate to sustained revenue growth if utilization per hospital is low
- Competing vascular repair products and techniques could limit market penetration
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3381591 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | Press Release | $0.4400 | awaiting T+60 | — | $0.4010 (−8.86%) |
Aug 19, 2026 9w ago | Press Release | $0.7349 | awaiting T+60 | — | $0.4010 (−45.43%) |
Aug 12, 2026 10w ago | 8-K | $0.6650 | awaiting T+60 | — | $0.4010 (−39.70%) |
Aug 12, 2026 10w ago | Press Release | $0.6650 | awaiting T+60 | — | $0.4010 (−39.70%) |
Aug 7, 2026 11w ago | Press Release | $0.7180 | awaiting T+60 | — | $0.4010 (−44.15%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.06 $0.5790 | ▼ −45.12% | ▼ −47.90% | $0.4010 (−61.99%) |
Jun 11, 2026 19w ago | 8-K | $1.06 $0.5790 | ▲ +45.12% | ▲ +47.90% | $0.4010 (+61.99%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4010 (+62.87%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4010 (+62.87%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▼ −44.92% | ▼ −48.74% | $0.4010 (−62.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers